Michael Sikorsky, DO
Pain Medicine · Bloomfield Hills, MINPI 1629043955
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Nevro Corp. accounts for 80.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $8,493 and has fallen 85.2% since, to $1,256 in 2025. Among pain medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $70.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$16K
- Medtronic$1K
- Globus Medical$723
- Vertos Medical, Inc.$401
- AbbVie$267
- Collegium Pharmaceutical, Inc.$231
- plus $857 from 19 others
Across 2 payments — averaging $4275.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Relievant Medsystems, Inc.$9K
What the payments were for
- Consulting fees$7,12537%
- Speaking & faculty fees$5,40028%
- Travel & lodging$4102%
- Food & beverage$6,29433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 125 | $15,506 |
| Medtronic(2 entities) | 46 | $1,244 |
| Globus Medical | 31 | $723 |
| Vertos Medical, Inc. | 9 | $401 |
| AbbVie(2 entities) | 13 | $267 |
| Collegium Pharmaceutical, Inc. | 11 | $231 |
| Nalu Medical, Inc. | 7 | $164 |
| Saluda Medical Americas, Inc. | 3 | $138 |
| Relievant Medsystems, Inc. | 1 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $65 |
| Stryker | 1 | $61 |
| Tersera Therapeutics LLC | 2 | $50 |
| Fidia Pharma USA Inc. | 2 | $49 |
| Pfizer | 2 | $28 |
| Pacira Pharmaceuticals Incorporated | 1 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Novartis | 2 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Spinal Simplicity, LLC | 1 | $20 |
| Vertex | 1 | $20 |
| Biotronik NRO, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Piramal Critical Care | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$9,600
- Omnia$2,879
- Senza$675
- mild Device Kit$304
- INTELLIS ADAPTIVESTIM$171
- INCEPTIV$146
- INTELLIS$104
How this compares
$19,229 in reported general payments places this provider in the 90th percentile of 139 pain medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 78 | $66,988 |
| Levorphanol Tartrate | 11 | $55,365 |
| Oxymorphone Hcl ErOxymorphone Hcl | 25 | $38,856 |
| Xtampza ErOxycodone Myristate | 35 | $33,909 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,175 | $26,013 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,314 | $25,028 |
| Buprenorphine | 130 | $22,096 |
| Fentanyl | 226 | $20,928 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $17,778 |
| Oxycodone Hcl | 693 | $17,337 |
| LinzessLinaclotide | 27 | $16,409 |
| Tramadol Hcl ErTramadol Hcl | 235 | $14,460 |
| Gabapentin | 777 | $14,390 |
| Morphine Sulfate ErMorphine Sulfate | 381 | $10,617 |
| Pregabalin | 623 | $9,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $231 | $33,90935 claims |
| AbbVieLinzess | $267 | $16,40927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 139 pain medicine providers in Michigan.
Other pain medicine in Bloomfield Hills
- Todd LiningerBloomfield Hills$11K
- James HonetBloomfield Hills$10K
- Alexander TsinbergBloomfield Hills$6K
- Marc WittenbergBloomfield Hills$4K
- Harry SukumaranRochester Hills$304K
- Nasir KhatriFlint$133K
- Yijia ChuGrand Rapids$88K
- Mark MounayerSouthfield$85K
- Jeffrey RosenbergCanton$44K
- Alexander TurfeWyandotte$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.